A total of 173 diabetic patients with lesions at moderate risk of restenosis ( exclusion criteria : diameter < 2.5 mm or length > 28 mm in vessels < 3mm , chronic occlusion ) were randomized to a titanium group ( 83 patients ) or an everolimus group ( 90 patients ) .